Protara Therapeutics, Inc. (TARA) Corporate Subsidiaries
Protara Therapeutics, Inc. (TARA) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: TARA
CIK: 1359931
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2021 12:00:00 AM
Lead Engagement PartnerJeremiah Ward
Audit LocationNew York, New York, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-13 | — | SCHEDULE 13G/A Filing | 0001274173-26-000205 | View SEC Doc Filr Page |
| S-8 | 2026-08-11 | — | REGISTRATION STATEMENT | 0001213900-26-087781 | View SEC Doc Filr Page |
| 10-Q | 2026-08-11 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-087508 | View SEC Doc Filr Page |
| 8-K | 2026-08-11 | 2026-08-11 | CURRENT REPORT | 0001213900-26-087506 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-07 | — | SCHEDULE 13G/A Filing | 0001104659-26-081389 | View SEC Doc Filr Page |
| 4 | 2026-07-01 | 2026-06-29 | PRIMARY DOCUMENT | 0001213900-26-074238 | View SEC Doc Filr Page |
| 8-K | 2026-06-29 | 2026-06-26 | CURRENT REPORT | 0001213900-26-073184 | View SEC Doc Filr Page |
| 144 | 2026-06-29 | — | 144 Filing | 0001950047-26-006626 | View SEC Doc Filr Page |
| 4 | 2026-06-16 | 2026-06-15 | PRIMARY DOCUMENT | 0001213900-26-069250 | View SEC Doc Filr Page |
| 4 | 2026-06-16 | 2026-06-15 | PRIMARY DOCUMENT | 0001213900-26-069249 | View SEC Doc Filr Page |
| 4 | 2026-06-16 | 2026-06-15 | PRIMARY DOCUMENT | 0001213900-26-069248 | View SEC Doc Filr Page |
| 4 | 2026-06-16 | 2026-06-15 | PRIMARY DOCUMENT | 0001213900-26-069247 | View SEC Doc Filr Page |
| 4 | 2026-06-16 | 2026-06-15 | PRIMARY DOCUMENT | 0001213900-26-069246 | View SEC Doc Filr Page |
| 4 | 2026-06-16 | 2026-06-15 | PRIMARY DOCUMENT | 0001213900-26-069245 | View SEC Doc Filr Page |
| 4 | 2026-06-16 | 2026-06-15 | PRIMARY DOCUMENT | 0001213900-26-069244 | View SEC Doc Filr Page |
| 4 | 2026-06-16 | 2026-06-15 | PRIMARY DOCUMENT | 0001213900-26-069243 | View SEC Doc Filr Page |
| 8-K | 2026-06-15 | 2026-06-12 | CURRENT REPORT | 0001213900-26-068774 | View SEC Doc Filr Page |
| 4 | 2026-06-03 | 2026-06-02 | PRIMARY DOCUMENT | 0001213900-26-064792 | View SEC Doc Filr Page |
| 424B5 | 2026-05-28 | — | PROSPECTUS SUPPLEMENT | 0001213900-26-062153 | View SEC Doc Filr Page |
| EFFECT | 2026-05-22 | — | EFFECT Filing | 9999999995-26-001748 | View SEC Doc Filr Page |
| CORRESP | 2026-05-20 | — | CORRESP Filing | 0001213900-26-059250 | View SEC Doc Filr Page |
| UPLOAD | 2026-05-19 | — | UPLOAD Filing | 0000000000-26-005137 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001274173-26-000151 | View SEC Doc Filr Page |
| S-3 | 2026-05-14 | — | REGISTRATION STATEMENT | 0001213900-26-056057 | View SEC Doc Filr Page |
| 10-Q | 2026-05-13 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-055463 | View SEC Doc Filr Page |